You searched for warning letter - Page 3 of 23

Weekly reads: Altos Labs aging supplements pub, destructive NIH cuts, FDA warning, HSCs

February 9, 2025 / Professor Paul Knoepfler, Ph.D. / 3 Comments

When I think of so-called aging supplements, visions of snake oil dance in my head. Possible benefits of supplements more generally have mostly not held up to long-term research. Supplements have risks too and so do purported longevity supplements. These pills claiming to fight aging are more in the realm of stem cell supplements that […]

Weekly reads: Altos Labs aging supplements pub, destructive NIH cuts, FDA warning, HSCs Read More »

Weekly reads: NIH freeze even before RFK confirmation, FDA warnings, RP stem cell trial data

January 26, 2025 / Professor Paul Knoepfler, Ph.D. / 6 Comments

RFK isn’t even confirmed as HHS Secretary and things are going south already with an NIH freeze. What do I mean? NIH freeze could do lasting damage to biomedical research The Trump Administration has frozen many NIH processes including meetings such as study sections that evaluate grant proposals. No study sections means almost no new

Weekly reads: NIH freeze even before RFK confirmation, FDA warnings, RP stem cell trial data Read More »

Weekly reads: intermittent fasting and stem cells, vet warning, blastemas

December 22, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

Intermittent fasting must be good for stem cells, right? It’s not so clear. Like many things in biology, intermittent fasting can have seemingly opposite effects. Before we get into that, the news of the week is that the FDA approved Mesoblast’s Ryoncil MSC drug for some cases of pediatric GvHD. This has sparked lively discussion.

Weekly reads: intermittent fasting and stem cells, vet warning, blastemas Read More »

Regener-Eyes maker gets FDA warning on amniotic eye drops

September 12, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

The FDA alerted the public about issues related to amniotic eye drops last year and now the agency just warned the manufacturer of one such product called Regener-Eyes. The manufacturer is Regenerative Processing Plant, LLC. The warning letter was addressed to its owner, Carl R. Harrell, MD. What’s the deal with this warning? Let’s start

Regener-Eyes maker gets FDA warning on amniotic eye drops Read More »

Weekly reads: stem cell shampoo, Neobiosis FDA warning, trogocytosis

August 11, 2024 / Professor Paul Knoepfler, Ph.D. / 7 Comments

Even for a stem cell research wonk like me the broader regenerative arena never ceases to surprise me with the latest thing being stem cell shampoo. Stem cell shampoo A news item that seems promotional discussed the stem cell shampoo as yielding positive results. So after you are done with your vampire facelift, stem cell

Weekly reads: stem cell shampoo, Neobiosis FDA warning, trogocytosis Read More »

Recommend reads: FDA SVF warning, big Aspen grant, CSI finale invokes stem cells

May 26, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

One of the most contentious areas in the regenerative medicine arena is whether a fat tissue product called stromal vascular fraction or SVF is a drug. The FDA says SVF, even in autologous form, is a drug. It is seeking an injunction against a California-based network of SVF clinics but lost the initial case. That

Recommend reads: FDA SVF warning, big Aspen grant, CSI finale invokes stem cells Read More »

Weekly reads: Alzheimer’s & lipid droplets, stem cells for COPD, fecal tx warning, med school teaching

March 24, 2024 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

So many things go wrong during the lead up to clinically-evident Alzheimer’s disease. This complex disease pathway has, in turn, led to a vast array of approaches to try to treat or prevent Alzheimer’s. Most of these efforts one way or another have something to do with the amyloid plaques and tangles that accumulate in the

Weekly reads: Alzheimer’s & lipid droplets, stem cells for COPD, fecal tx warning, med school teaching Read More »

Weekly reads: MiMedX & Kimera Labs FDA warnings, NYT on Bryan Johnson, MUSE cell trial

January 21, 2024 / Professor Paul Knoepfler, Ph.D. / 10 Comments

Placental biologics firm MiMedx and exosome company Kimera Labs both recently received FDA warning letters. The letter to MiMedx was related to its placental biologics products and procedures. The new warning to Kimera Labs was about its exosome products and an amniotic product. Let’s compare these letters starting with the one to MiMedX. MiMedx warning letter

Weekly reads: MiMedX & Kimera Labs FDA warnings, NYT on Bryan Johnson, MUSE cell trial Read More »

3rd Invitrx warning highlights FDA oversight weakness

January 4, 2023 / Professor Paul Knoepfler, Ph.D. / 8 Comments

The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past

3rd Invitrx warning highlights FDA oversight weakness Read More »

Search Results for: warning letter